What Peptide Works Like Ozempic? GLP-1 Alternatives Explained

Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist. It works by mimicking the GLP-1 hormone your body naturally releases after eating, which:

• Reduces appetite and food cravings
• Slows gastric emptying (you feel full longer)
• Improves insulin sensitivity
• Reduces blood sugar spikes

Any peptide that "works like Ozempic" needs to activate GLP-1 receptors. Here are the options, from closest alternatives to more distant relatives.

Wegovy is literally the same molecule as Ozempic — semaglutide — but FDA-approved specifically for weight loss at a higher maintenance dose (2.4mg vs 1.0mg for Ozempic).

If your goal is weight loss rather than diabetes management, Wegovy is the correct prescription. Use our GLP-1 titration calculator for the dosing schedule.

Compounded semaglutide is the same active ingredient as Ozempic/Wegovy, prepared by compounding pharmacies at a fraction of the cost. It has been a popular alternative, though the FDA has been tightening regulations on compounded GLP-1s.

Pros: Same molecule, much cheaper ($150-$400/month vs $1,000+) Cons: Quality varies by pharmacy, regulatory landscape is shifting

Use our cost calculator to compare compounded vs brand pricing.

Tirzepatide is not identical to Ozempic but is its closest competitor — and arguably better. It's a dual GLP-1/GIP agonist that was proven superior to semaglutide in head-to-head trials (SURMOUNT-5), achieving 20.2% weight loss vs 13.7% for semaglutide.

Why choose tirzepatide over semaglutide:

• Greater weight loss in clinical trials
• Dual mechanism (GLP-1 + GIP) for enhanced metabolic effects
• Available as Mounjaro (diabetes) and Zepbound (weight loss)

Liraglutide is an older GLP-1 agonist and the closest relative to semaglutide. It was the first GLP-1 approved for weight loss (as Saxenda).

How it compares to Ozempic:

• Same GLP-1 mechanism, less potent (~8% weight loss vs 13-15%)
• Requires daily injection (vs weekly for semaglutide)
• Longest safety track record (6+ years post-market data)
• Approved for ages 12+ (Ozempic/Wegovy are adult-only for weight loss)

Exenatide was the first GLP-1 agonist approved (2005). Available as Byetta (twice daily) or Bydureon (weekly extended-release).

How it compares to Ozempic:

• Similar mechanism but less weight loss (~5-6%)
• Derived from Gila monster venom (exendin-4)
• Much less prescribed now due to superior newer options

Retatrutide is the next generation — a triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 TRIUMPH-4 trial results (December 2025) showed 28.7% weight loss, far surpassing Ozempic.

Status: Not yet FDA-approved. Expected approval ~2027. Not available outside clinical trials.

Some people search for Ozempic alternatives that don't involve GLP-1 agonists:

• AOD-9604 — An HGH fragment marketed for fat loss, but clinical trials showed disappointing results and development was abandoned.
• Tesofensine — An oral appetite suppressant (not a peptide) that showed ~10% weight loss. Not FDA-approved.
• MOTS-c — A mitochondrial peptide studied for metabolic benefits, but early-stage research.

None of these work through the GLP-1 pathway like Ozempic, and none have comparable clinical evidence for weight loss.